Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00314145
Other study ID # H-040-009
Secondary ID
Status Completed
Phase Phase 3
First received April 11, 2006
Last updated December 4, 2012
Start date November 2005
Est. completion date November 2006

Study information

Verified date December 2012
Source Sanofi
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug AdministrationAustralia: Department of Health and Ageing Therapeutic Goods Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine non-inferiority in seroconversion and to compare the safety and tolerability between ChimeriVaxTM-JE and JE-VAX to the respective homologous virus strain after completion of vaccination course.


Recruitment information / eligibility

Status Completed
Enrollment 820
Est. completion date November 2006
Est. primary completion date June 2006
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Subjects aged 18 or above

- Subjects in good general health.

- Females must have negative pregnancy test and be using adequate form of contraception

Exclusion Criteria:

- History of vaccination/infection with JE or Yellow fever or other flaviviruses

- History of residence/travel to flavivirus endemic regions

- History of anaphylaxis/serious adverse reactions

- Administration of vaccine within 30 days of study or during treatment period

- Clinically significant physical exam/medical history/lab abnormalities

- Pregnancy

- Excessive alcohol/drug abuse

- Hypersensitivity to constituents of JE-VAX®

- Blood transfusion/treatment with blood product within 6months of study and during study treatment period

- Known/suspected immunodeficiency

- Compromised blood brain barrier

- Employees of Clinical Research Organization (CRO)/study site staff

- Any other condition which would exclude subject.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention


Intervention

Biological:
ChimeriVax™-JE
0.5 mL, Subcutaneous (ChimeriVax™-JE); 1.0 mL, (Saline)
JE-VAX®
0.5 mL, Subcutaneous (JE-Vax®); 1.0 mL, (Saline)

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Sanofi

Countries where clinical trial is conducted

United States,  Australia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Japanese Encephalitis (Homologous Virus) Seroconversion Following Either ChimeriVax™-JE or JE-Vax® Vaccination Antibodies to Japanese encephalitis (JE) were measured by 50% plaque reduction neutralization test (PRNT50). Seroconversion was defined as a titer of = 1:10. Up to Day 60 post-first vaccination No
Primary Number of Participants Reporting Treatment Emergent Local Adverse Events and Treatment Emergent Systemic Reactions Post-Vaccination With Either ChimeriVax™-JE or JE-Vax® Treatment emergent local adverse events: Pain, Erythema, Pruritus, Swelling, Induration, and others as reported.
Treatment emergent systemic reactions: Fatigue, Malaise, Chills, Pyrexia, Headache, Myalgia, Arthralgia, Diarrhea, Nausea, Vomiting, and Rash.
Day 0 (Pre-vaccination) up to 60 days post-first vaccination No
Secondary Neutralizing Antibody Geometric Mean Titers (GMTs) to Japanese Encephalitis (Homologous Virus) Following Either ChimeriVax™-JE or JE-Vax® Vaccination Antibodies to Japanese encephalitis (JE) were measured by 50% plaque reduction neutralization test (PRNT50). Up to Day 60 post-first vaccination No
Secondary Number of Participants in the Japanese Encephalitis (Homologous Virus) Neutralizing Antibody Titer Categories on Day 60 Following Either ChimeriVax™-JE or JE-Vax® Vaccination Antibodies to Japanese encephalitis (JE) were measured by 50% plaque reduction neutralization test (PRNT50). Day 60 post-first vaccination No
See also
  Status Clinical Trial Phase
Completed NCT03282370 - Evaluate Safety and Immunogenicity of a Vero Cell-Derived JE Vaccine in 9-24 Months of Age Children in Vietnam Phase 3
Recruiting NCT05568953 - An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity Phase 2
Completed NCT00776230 - Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post Filling Phase 3
Completed NCT00594958 - Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51 Phase 3
Completed NCT00604708 - Immunogenicity Study of the Japanese Encephalitis Vaccine IC51 Phase 3
Completed NCT00596271 - Concomitant Vaccination With the Japanese Encephalitis Vaccine IC51 and HARVIX® 1440 Phase 3
Completed NCT00595790 - Rapid Immunization Study of the Japanese Encephalitis Vaccine IC51 Phase 3
Not yet recruiting NCT01954810 - Antibody Response of a Boosted Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Phase 4
Completed NCT01246479 - Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study Phase 3
Completed NCT00596102 - Longterm Immunogenicity of the Japanese Encephalitis Vaccine IC51 Phase 3
Completed NCT00314132 - Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis. Phase 3
Completed NCT00595270 - Long Term Persistence and Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51 Phase 3
Completed NCT00605085 - Safety and Tolerability of the Japanese Encephalitis Vaccine IC51 Phase 3
Active, not recruiting NCT01981967 - Post-licensure Safety Study of IMOJEV® in Thailand Phase 4
Completed NCT01466387 - A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults Phase 3
Completed NCT00981630 - Study of Live Attenuated ChimeriVax™-Japanese Encephalitis Vaccine Phase 2
Completed NCT01656200 - A Prospective, Open Label Study of Human T Cell Responses to Live Attenuated Japanese Encephalitis Vaccine SA14-14-2 Phase 4
Completed NCT01567865 - Lot-to-lot Consistency Trial of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine Phase 4
Unknown status NCT01163123 - Seroepidemiology of Japanese Encephalitis Virus Infection in Hualien, Taiwan N/A
Completed NCT01856205 - Safety and Efficacy Study of Intravenous Immunoglobulin to Treat Japanese Encephalitis Phase 2